Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridging Radiation for Lisocabtagene Maraleucel in Relapsed B-Cell Lymphoma
NCT05621096Phase 1Active, not recruiting
- Sponsor
- University of Nebraska
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lisocabtagene maraleucel in B cell lymphoma, sponsored by University of Nebraska. Primary endpoint: Feasibility of the intervention at 90 days. Started Mar 2023; status: active, not recruiting.
02
Drugs
lisocabtagene maraleucel
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05621096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621096.